title: Inflammation-mediated obesity and insulin resistance as targets for nutraceuticals.
abstract: Obesity-induced inflammation plays an important role in the development of insulin resistance, type 2 diabetes (T2D), and metabolic dysfunctions. Chronic activation of proinflammatory pathways within insulin target cells can lead to obesity-related insulin resistance. The inflammatory mediators consist of immune cells, cytokines, adipokines, and inflammatory signaling molecules. Targeting obesity-associated inflammation has been shown to protect experimental animals and human subjects from obesity-induced insulin resistance. Modulation of the inflammatory responses associated with obesity may help prevent or improve obesity-induced metabolic dysfunctions. In this review, we introduce the beneficial effects of nutraceuticals for targeting inflammation in the treatment of obesity-induced insulin resistance and metabolic dysfunctions.
authors.affiliation: Korea Food Research Institute, Gyongki-do, Republic of Korea.
authors.forename: Myung-Sunny
authors.initials: MS
authors.lastname: Kim
authors.forename: Myeong Soo
authors.initials: MS
authors.lastname: Lee
authors.forename: Dae Young
authors.initials: DY
authors.lastname: Kown
mesh_terms: D054392:Adipokines / Q000378:metabolism; D000818:Animals; D016207:Cytokines / Q000378:metabolism; D019587:Dietary Supplements; D006801:Humans; D007249:Inflammation / Q000150:complications / Q000178:diet therapy* / Q000378:metabolism; D018836:Inflammation Mediators / Q000378:metabolism; D007333:Insulin Resistance / Q000502:physiology*; D009765:Obesity / Q000209:etiology*; D015398:Signal Transduction
chemical_list: D054392:Adipokines; D016207:Cytokines; D018836:Inflammation Mediators